Effect of atorvastatin on low-density lipoprotein subpopulations and comparison between indicators of plasma atherogenicity: A pilot study

Angiology

Volumn 65, Issue 9, 2014, Pages 794-799

  Kucera, Marek ^a   Oravec, Stanislav ^a   Hirnerova, Eva ^a   Huckova, Nada ^a   Celecova, Zuzana ^a   Gaspar, Ludovit ^a   Banach, Maciej ^b  

^a Comenius University ^*  (Slovakia)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

apolipoprotein B; atherogenic dyslipidemia; atherogenic index of plasma; atorvastatin; cardiovascular risk; small dense LDL

Indexed keywords

APOLIPOPROTEIN B; ATORVASTATIN; BIOLOGICAL MARKER; CHOLESTEROL; HEPTANOIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; PYRROLE DERIVATIVE; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; ATHEROGENIC DYSLIPIDEMIA; ATHEROGENIC INDEX OF PLASMA; ATHEROSCLEROSIS; BLOOD; CARDIOVASCULAR RISK; COMPARATIVE STUDY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPOPROTEINEMIA; MALE; MIDDLE AGED; PILOT STUDY; SMALL-DENSE LDL; TIME; TREATMENT OUTCOME; VERY ELDERLY;

APOLIPOPROTEIN B; ATHEROGENIC DYSLIPIDEMIA; ATHEROGENIC INDEX OF PLASMA; ATORVASTATIN; CARDIOVASCULAR RISK; SMALL-DENSE LDL;

ADULT; AGED; AGED, 80 AND OVER; APOLIPOPROTEINS B; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CHOLESTEROL; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; HYPERLIPOPROTEINEMIAS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; PILOT PROJECTS; PYRROLES; TIME FACTORS; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 84893856627     PISSN: 00033197     EISSN: 19401574     Source Type: Journal    
DOI: 10.1177/0003319713507476     Document Type: Article

References (21)

1. Gang Hu, Qing Q, Tuomilehto J, et al. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med. 2004;164(10):1066-1076.
2. Oravec S, Gruber K, Dostal E. Hyper-betalipoproteinemia LDL 1,2: a newly identified nonatherogenic hypercholesterolemia in a group of hypercholesterolemic subjects. Neuro Endocrinol Lett. 2011;32(3):322-327.
3. Sasaki S, Kuwahara N, Kunitomo K, et al. Effects of atorvastatin on oxidized low-density lipoprotein, low density lipoprotein subfraction distribution, and remnant lipoprotein in patients with mixed hyperlipoproteinemia. Am J Cardiol. 2002;89(4):386-389.
4. Pontrelli L, Parris W, Adeli K, Cheung RC. Atorvastatin treatment beneficially alters the lipoprotein profile and increases low density lipoprotein particle diameter in patients with combined dyslipidemia and impaired fasting glucose in type 2 diabetes. Metabolism. 2002;51(3):334-342.
5. Schwartz GG, Olsson AG, Ezekowitz MB, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. the MIRACL study: a randomized controlled trial. JAMA. 2001;285(13):1711-1718.
6. Dobiášová M. Atherogenic Index of plasma [log(triglycerides/HDL-cholesterol)]: theoretical and practical implications. Clin Chem. 2004;50(7):1113-1115.
7. Katsiki N, Nikolic D, Montalto G, Banach M, Mikhailidis DP, Rizzo M. The role of fibrate treatment in dylipidemia: an overview. Curr Pharm Des. 2013;19(17):3124-3131.
8. Katsiki N, Athyros VG, Karagiannis A, Mikhailidis DP. Ezetimibe and low density lipoprotein subfractions: an ongoing debate. Cur Med Res Opin. 2011;27(3):693-695.
9. Rizzo M, Barylski M, Rizvi AA, Montalto G, Mikhailidis DP, Banach M. Combined dyslipidemia: should the focus be LDL cholesterol or atherogenic dyslipidemia? Curr PharmDes. 2013;19(21):3858-3868.
10. Rizzo M, Banach M, Montalto G, Mikhailidis DP. Lipid-lowering therapies and achievement of LDL-cholesterol targets. Arch Med Sci. 2012;8(4):598-600.
11. Barylski M, Małyszko J, Rysz J, Mys̈liwiec M, Banach M. Lipids, blood pressure, kidney - what was new in 2011? Arch Med Sci. 2011;7(6):1055-1066.
12. Collins R, Armitage J, Parish S, Sleigh P, Peto R; Heart Protection Study Collaborative Group. Heart protection study collaborative group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003;361(9374):2005-2016.
13. Miller M, Cannon CP, Murphy SA, et al. Impact of triglyceride levels beyond low density lipoprotein cholesterol after acute coronary syndrome in the PROVE-IT TIMI 22 trial. J Am Coll Cardiol. 2008;51(7):724-730.
14. Oravec S. Lipoproteiny plazmy. In: Oravec S, ed. Lipoproteíny v diagnostike interných ochorení. Bratislava: VEDA; 1999:31.
15. Petrov AM, Zefirov AL. Cholesterol and lipid rafts in the biological membranes. role in the release, reception and ion channel functions. Usp Fiziol Nauk. 2013;44(1):17-38.
16. Banach M, Nikfar S, Rahimi R et al. The effects of statins on blood pressure in normotensive or hypertensive subjects - a meta-analysis of randomized controlled trials [published online April 18, 2013]. Int J Cardiol. 2013. doi:10.1016/j.ijcard.2013.03.068.
17. Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E. High apolipoprotein B, low apolipoprotein A-1, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet. 2001;15(9298):2026-2033.
18. Otocka-Kmiecik A, Mikhailidis DP, Nicholls SJ, Davidson M, Rysz J, Banach M. Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease? Prog Lipid Res. 2012;51(4):314-324.
19. Mikhailidis DP, Elisaf M, Rizzo M, et al. "European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses. Curr Vasc Pharmacol. 2011;9(5):533-571.
20. Rizzo M, Rini GB, Berneis K. Effects of statins, fibrates, rosuvastatin, and ezetimibe beyond cholesterol: the modulation of LDL size and subclasses in high-risk patients. Adv Ther. 2007;24(3):575-582.
21. Nikolic D, Katsiki N, Montalto G, Isenovic ER, Mikhailidis DP, Rizzo M. Lipoprotein subfractions in metabolic syndrome and obesity: clinical significance and therapeutic approaches. Nutrients. 2013;5(3):928-948.